Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Manifestations in Post-COVID-19 Patients
Author(s): Angela Cozma , Violeta Briciu , Adela Viviana Sitar-Tăut , et al Added: 4 weeks ago

Heart Failure

Prevention & Chronic Conditions
Research Area(s) / Expertise:
ECO 24: Long-Term Weight Loss in the SELECT trial
Author(s): Donna H Ryan Added: 11 months ago
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to… View more

Heart Failure

Prevention & Chronic Conditions
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 6 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Ashleigh Long
Job title: Cardiology Fellow
Personal History Dr Ashleigh Amanda Long was born in 1981 and is from Lexington, Kentucky.1 Her interests are advanced heart failure, interventional cardiology, clinical trials and patient safety.3 Academic History In 2010, Dr Long completed her PhD in Biological Sciences at Vanderbilt University, Nashville, Tennessee.2, 4 She graduated from the University of Kentucky College of… View more
Long-Term Survival Benefit Associated with CRT-D Compared to ICD in HF in the RAFT Trial
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Brad WilsonRAFT, a new extended follow-up trial (NCT00251251) showed insight into the survival benefit associated with coronary resynchronization therapy defibrillator (CRT-D) as compared to implantable cardioverter-defibrillator (ICD) in patients with heart failure.Methodology:The Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) is a randomized trial which aimed… View more
Research Area(s) / Expertise: